Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
459
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
430
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

622
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

612
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
612

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Caudal esophageal achalasia in a Quarter Horse colt.

Journal of veterinary internal medicine·2026
Same author

<i>Clostridium perfringens</i> type C-associated emphysematous gastritis in a dog with pancreatic disease.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·2026
Same author

Assessment of Biological Variation of Hemostatic Parameters in Healthy Dogs Using a Point-Of-Care Viscoelastic Coagulometer.

Veterinary clinical pathology·2026
Same author

Dogs with chronic enteropathy and low disease activity show signs consistent with compromised emotional health compared to matched healthy control dogs.

Journal of the American Veterinary Medical Association·2026
Same author

Abundance of bacteria and histopathologic findings in the small intestinal mucosa of dogs with chronic inflammatory enteropathies.

PloS one·2025
Same author

<i>Escherichia coli</i>-associated renal malakoplakia in 2 dogs.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·2025
Same journal

Acute-onset neurologic signs in an indoor/outdoor domestic shorthair cat.

Journal of the American Veterinary Medical Association·2026
Same journal

Progressive exophthalmos and strabismus in a 4-year-old Jersey steer.

Journal of the American Veterinary Medical Association·2026
Same journal

Orchiectomy in horses: closed technique and primary closure of the incision.

Journal of the American Veterinary Medical Association·2026
Same journal

Stranguria in a 3-month-old Holstein-Friesian heifer.

Journal of the American Veterinary Medical Association·2026
Same journal

Caudal vena cava-to-aorta ratio in hemodynamically stable and unstable client-owned rabbits.

Journal of the American Veterinary Medical Association·2026
Same journal

Dogs with intrahepatic portal hypertension of congenital cause have distinct diagnostic findings compared to dogs with chronic hepatitis-related portal hypertension.

Journal of the American Veterinary Medical Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 11, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K

在患有慢性肠道病变的狗中,重复的便微生物群移植可以降低疾病活性和皮质类固醇使用.

Linda Toresson1,2, Ulrika Ludvigsson2, Gunilla Olmedal2

  • 11Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX.

Journal of the American Veterinary Medical Association
|November 12, 2025
PubMed
概括
此摘要是机器生成的。

重复的便微生物群移植 (FMT) 有效地治疗了狗的慢性肠道病变 (CE),特别是那些患有轻度失生症的狗. 这种方法减少了耐药病例中的疾病活性和皮质类固醇依赖.

关键词:
胆酸代谢失调导致胆酸代谢失调慢性肠道病变 慢性肠道病变皮质类固醇是什么这种疾病叫做dysbiosis.便微生物群移植

更多相关视频

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.3K

相关实验视频

Last Updated: Jan 11, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.3K

科学领域:

  • 兽医医学 兽医医学 兽医医学
  • 胃肠病学 胃肠病学
  • 微生物组研究 微生物组研究

背景情况:

  • 狗的慢性肠道病变 (CE) 是一种具有挑战性的疾病,通常需要先进的治疗策略.
  • 耐火性CE病例呈现出对新型治疗选择的显著临床需求.
  • 便微生物种移植 (FMT) 正成为通过调节肠道微生物组来治疗胃肠道疾病的潜在治疗方法.

研究的目的:

  • 评估重复便微生物群移植 (FMT) 作为耐火性慢性肠道病变 (CE) 的狗的辅助治疗的疗效.
  • 评估临床结果和便参数,包括失生症指数,胆酸和calprotectin,在FMT之后.
  • 为了确定反复 FMT 响应的预测因子,在具有 CE 的狗中.

主要方法:

  • 一项前性的纵向观察研究,涉及39只耐火CE.狗.
  • 狗在一个月内接受了2到3次直肠FMT.
  • 在6个月的时间里,使用犬炎性肠病活动指数 (CIBDAI) 和便分析进行了临床评估.

主要成果:

  • 39只狗中有28只 (71.8%) 对FMT有反应,其中13只狗的皮质类固醇水平逐渐降低.
  • 与非响应者相比,长期响应者 (LLRs) 的基线失生症指数明显较低,二次未结合便胆酸的百分比较高.
  • 在FMT后的LLR中,dysbiosis指数显著下降,而该组的临床改善持续了6个月.

结论:

  • 重复的FMT作为一种有效的辅助治疗耐火性CE在狗,特别是那些微小或中度的dysbiosis.
  • 预先存在的明显失调和胆酸代谢不良可能与对FMT的反应不佳或短暂相关.
  • 对于没有反应的病例,需要对优化FMT协议进行进一步的调查,可能包括重复管理.